Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2025-03-28 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
2024年年度审计报告
Audit Report / Information Classification · 95% confidence The document is titled as an "审计报告" (Audit Report) issued by Da Hua Certified Public Accountants for 华兰生物工程股份有限公司 covering the fiscal year from January 1, 2024 to December 31, 2024. It contains detailed audit opinions, key audit matters, and extensive financial statements including consolidated balance sheets, income statements, cash flow statements, and equity changes. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement. The content focuses on the audit of financial statements and the auditor's opinion, which matches the definition of an Audit Report / Information (AR). It is not an Annual Report (10-K) because it lacks management discussion and broader company information beyond the audit and financial statements. Therefore, the correct classification is AR with high confidence. FY 2024
2025-03-28 Chinese
2024年独立董事年度述职报告(王云龙)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2024 Annual Work Report" for a company, detailing the independent director's activities, attendance at board and committee meetings, oversight of financial reporting and audits, and other governance-related duties during the 2024 fiscal year. It includes detailed descriptions of the director's role, participation in meetings, opinions on profit distribution, auditor reappointment, and other governance matters. The document is a formal report by an independent director on their annual duties and performance, not a general annual report, audit report, or other financial filing. It is not a brief announcement or a proxy statement but a detailed management/governance-related report. Therefore, the best fitting category is Board/Management Information (MANG), which covers announcements of changes or reports related to the company's board or senior management activities. The document is over 5,000 characters and contains substantive content about board activities and governance, not just a notice or announcement, so it is not RPA or RNS.
2025-03-28 Chinese
2024年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the "2024 Annual Report Summary" of 华兰生物工程股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2024, including total assets, net profit, revenue, and quarterly financial data. It also includes comprehensive business descriptions, product information, and strategic developments for the year. The length of the document (15,000 characters) and the presence of substantive financial and operational data confirm it is a full financial report rather than a brief announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2024
2025-03-28 Chinese
关于使用自有资金进行投资理财的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by the company 华兰生物工程股份有限公司 regarding the use of its own funds for investment and financial management. It details the investment purpose, amount, objects, authorization period, approval procedures, impact on the company, and risk control measures. The document is relatively short (1157 characters) and does not contain financial statements or detailed financial data. It is an update on the company's capital usage and financing activities rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2025-03-28 Chinese
监事会决议公告
AGM Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 15th meeting of the 8th Supervisory Board of Hualan Biological Engineering Inc. It includes approvals of the 2024 Supervisory Board Work Report, the 2024 Annual Report and its summary, the 2024 Financial Final Report, profit distribution proposals, accounting policy changes, internal control self-evaluation report, and other governance-related matters. The document references the 2024 Annual Report and other reports but does not contain the full annual report itself; rather, it states that these reports are published elsewhere (e.g., on the cninfo website) and that these resolutions will be submitted to the 2024 Annual General Meeting for approval. The document is 3816 characters long, which is relatively short and consistent with an announcement rather than a full report. The content is primarily about the meeting resolutions and approvals, not the full financial data or detailed report content. Therefore, this document is best classified as an AGM Information filing, as it relates to materials and resolutions from a general meeting or supervisory board meeting.
2025-03-28 Chinese
关于变更注册资本暨修订《公司章程》相关条款的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the change in registered capital and the corresponding amendments to the company's articles of association. It details the reduction in total shares due to the repurchase and cancellation of restricted stock and the resulting change in registered capital. The document also mentions that the amendments will be submitted to the 2024 annual shareholders' meeting for approval. There is no financial report, earnings data, or detailed financial statements included. The document is a formal announcement about capital changes and corporate governance amendments, fitting the category of Share Issue/Capital Change (SHA). The document length is short and focused on capital structure changes, not a full report or presentation.
2025-03-28 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.